AGIO Agios Pharmaceuticals, Inc. Loading...

Loading chart...
Top Calls

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
17:07
Oct 20
seedy19tron
Underappreciated AGIO PDUFA upside News
Flags AGIO as underappreciated ahead of an imminent PDUFA for its SCD drug, sees approval as likely, and cites a scenario for 25%+ upside depending on the label.
AGIO Agios Pharmaceuticals, Inc. Long 1ST — —

About AGIO Investor Commentary

Across the available history and selected sources, Buzzberg tracks AGIO (Agios Pharmaceuticals, Inc.) across 3 sources: 1 bullish vs 0 bearish calls from 3 authors. Historical directional balance: 25% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 4 total trade ideas tracked. Past 7 days, before deduplication: 1 bullish. Latest voices: seedy19tron.